Ignite Creation Date:
2024-05-05 @ 4:35 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00263965
Status:
TERMINATED
Last Update Posted:
2008-03-17
First Post:
2005-12-09
Brief Title:
ARAMIS Actions of tesaglitazaR on fAt Metabolism and Insulin Sensitivity
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A 16-Week Randomized Double-Blind Parallel-Group Multicenter Placebo- and Active- Metformin Controlled Study to Evaluate the Effect on Whole Body Insulin Sensitivity of Tesaglitazar Therapy When Administered to Patients With Type 2 Diabetes
Status:
TERMINATED
Status Verified Date:
2008-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The development program has been terminated
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a 16-week randomized double-blind parallel-group multi-center placebo- and active- metformin 15 g controlled study of tesaglitazar 1 mg in patients with type 2 diabetes After a 1-week enrollment period a 3 week placebo single blind run in period and 1-week placebo single-blind baseline measurement period the patients will be given the investigational product for 16 weeks in a double blind fashion Metformin will be titrated up during the first 3 weeks of the double-blind period The total study duration including enrollment run-in randomized treatment and follow-up is 29 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EudraCT No 2004-000350-24 | None | None | None |